Zhende Medical Stock Hits Day Low of CNY 91.65 Amid Price Pressure

Zhende Medical Co., a prominent player in the Pharmaceuticals & Biotechnology sector, experienced a notable decline today, with its stock price dropping by 3.47% on March 12, 2026. The stock reached an intraday low of CNY 91.65, reflecting a challenging trading session. Despite this downturn, Zhende Medical has shown resilience over the longer term, with a remarkable one-year performance of 331.07%, significantly outperforming the China Shanghai Composite, which recorded a gain of 22.46% during the same period. The company's year-to-date performance stands at 31.65%, again surpassing the broader market's 4.04% increase. However, the company faces some financial headwinds, as evidenced by a negative growth trajectory in net sales and operating profit over the past five years. The current debt-equity ratio is notably high at 5.96%, indicating potential financial strain. Additionally, the return on equity is at 6.50%, suggesting a fair valuation relative to its price-to-book ratio of 2.03. As Zhende Medical navigates these complexities, its stock performance remains a focal point for market observers.